Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-na√Øve Ph+ Acute Lymphoblastic Leukemia
The purpose of this study is to explore the efficacy and safety of the OVD chemotherapy-free regimen (Olverembatinib, venetoclax and dexamethasone) in patients with newly-diagnosed Ph+ALL.
Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia
DRUG: Olverembatinib plus venetoclax and dexamethasone
Complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) rates, Three years|Negative measurable residual disease (MRD) rates, Three years|Complete molecular remissions (CMR) rates, Three years|Progression-free survival (PFS), Three years
PRIMARY OBJECTIVES:

To determine the Complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) rates, the measurable residual disease (MRD) rates, the complete molecular remissions (CMR) rates and the progression-free survival (PFS) of the OVD chemotherapy-free regimen (Olverembatinib, venetoclax and dexamethasone) in patients with newly-diagnosed Ph+ALL.

SECONDARY OBJECTIVES:

To describe the toxicities of the OVD regimen. To assess the quality of life and overall survival of the OVD chemotherapy-free regimen in patients with newly-diagnosed Ph+ALL.